December 15, 2011FDA Will Not Require a Risk Evaluation and Mitigation Strategy in Connection With Corcept's Proposed Distribution of Korlym™ for Cushing's Syndrome

November 7, 2011Corcept Therapeutics Announces Third Quarter Results and Corporate and Development Update

August 22, 2011No FDA Advisory Committee Meeting Planned in Connection with New Drug Application for CORLUX for Cushing's Syndrome

August 22, 2011Gary C. Robb Joins Corcept as Chief Financial Officer

August 8, 2011Corcept Therapeutics Announces Second Quarter Results and Corporate and Development Update

June 30, 2011FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome

June 4, 2011Corcept Therapeutics Announces Detailed Findings from Phase 3 Study Which Show CORLUX Significantly Improves Clinical and Metabolic Manifestations of Cushing's Syndrome

June 1, 2011Corcept Therapeutics Announces Conference Call to Discuss Detailed Findings from CORLUX Phase 3 Trial in Cushing's Syndrome at the Endocrine Society's Annual Meeting

May 19, 2011Corcept Therapeutics to Present Detailed Findings from CORLUX Phase 3 Trial in Cushing's Syndrome at the Endocrine Society's Annual Meeting, June 4-7

May 4, 2011Corcept Therapeutics Announces First Quarter Results and Corporate and Development Update

April 15, 2011Corcept Therapeutics Announces NDA Submitted to the FDA for the Use of Corlux in Cushing’s Syndrome

March 31, 2011Corcept Therapeutics Announces NDA Submission to be Completed the Week of April 11, 2011

March 9, 2011Corcept Therapeutics Announces Fourth Quarter Results and Corporate and Development Update

January 26, 2011Corcept Therapeutics Announces Closing of $44.9 Million Underwritten Public Offering of Common Stock

January 11, 2011Corcept Therapeutics Announces Key Secondary Endpoint Was Met in Phase 3 Study of CORLUX for Cushing's Syndrome